Search

Displaying results 2601 - 2610 of 6951 in total
  1. Drug

    Chlormadinone acetate

    go.drugbank.com/drugs/DB15903
    ApprovedWithdrawn

    In 1972, the FDA withdrew its approval for the use of chlormadinone acetate in all products.

    Categories: Hormonal Contraceptives for Systemic Use
  2. Drug

    Cyanocobalamin Co-60

    go.drugbank.com/drugs/DB09387
    ApprovedWithdrawn

    Cyanocobalamin Co-60 was used for the diagnosis of pernicious anemia, but now it is withdrawn from the market in the US for unknown reasons.

  3. Drug

    Ulobetasol

    go.drugbank.com/drugs/DB00596
    Approved

    Ulobetasol is a highly potent corticosteroid. It is structurally related to clobetasol. Due to its high potency, it is mainly prescribed in the treatment of severe plaque psoriasis and corticosteroid responsive dermatoses. Ulobetasol was...

    Categories: Antipsoriatics for Topical Use, Corticosteroid Hormone Receptor Agonists
  4. Drug

    Mirikizumab

    go.drugbank.com/drugs/DB14910
    ApprovedInvestigational

    [L46237,L46257] Mirikizumab is approved in Japan[L46252] and received a positive opinion from the EMA's Committee for Medicinal Products for Human Use in March 2023. … [L46237] In April 2023, the US FDA declined to approve mirikizumab for the treatment of ulcerative colitis on the basis of manufacturing concerns.

  5. Drug

    Pitolisant

    go.drugbank.com/drugs/DB11642
    ApprovedInvestigational

    FDA approved the use of pitolisant in 2019 for excessive daytime sleepiness (EDS) associated with narcolepsy in adults.[L8063] … Commonly marketed under the trade name Wakix, oral pitolisant was approved by the EMA in 2016 [A183062] for the treatment of narcolepsy with or without cataplexy.

    Categories: Histamine-3 Receptor Antagonist/Inverse Agonist, Histamine-3 (H3) Receptor Antagonists/Inverse Agonists
  6. Drug

    Voacamine

    go.drugbank.com/drugs/DB04877
    Experimental

    It is an antimalarial drug approved for use in several African countries. Voacamine is also under investigation for use in modulating multidrug-resistance in tumor cells.

  7. Drug

    Roflumilast

    go.drugbank.com/drugs/DB01656
    ApprovedInvestigational

    [L46541] On December 15, 2023, the FDA approved a new topical foam formulation of roflumilast for the treatment of seborrheic dermatitis in patients aged 9 years and older.[L49281]

    Categories: Antipsoriatics for Topical Use, Drugs for Obstructive Airway Diseases
  8. Drug

    Aprepitant

    go.drugbank.com/drugs/DB00673
    ApprovedInvestigational

    Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting … Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CI NV).

    Categories: Neurokinin-1 Receptor Antagonists, Substance P/Neurokinin-1 Receptor Antagonist
  9. Drug

    Lanadelumab

    go.drugbank.com/drugs/DB14597
    ApprovedInvestigational

    Lanadelumab, also known as DX-2930, is a human IgG1 monoclonal antibody designed for subcutaneous self-injection. … [L4537] It has been granted priority review, breakthrough therapy, and orphan drug designations for rare diseases based on the results of clinical trials.

  10. Drug

    Dengue virus serotype 4

    go.drugbank.com/drugs/DB22667
    Approved

    [L53368] Qdenga was approved for use in the European Union in December 2022.[L53373] … [A274008] It is one of four serotypes covered by Qdenga, a live, attenuated, tetravalent vaccine used for the prevention of dengue disease.